{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:40:28Z","timestamp":1790829628460,"version":"4.1.0"},"reference-count":15,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Recent studies have demonstrated neutrophil overexpression of the polycythemia rubra vera-1 (PRV-1) gene in polycythemia vera (PV) but not in secondary or spurious polycythemia (SP). To validate as well as expand upon this novel observation, we conducted a prospective study of 88 subjects: 30 with PV, 22 with SP, 14 with essential thrombocythemia (ET), 12 with myelofibrosis with myeloid metaplasia (MMM), and 10 controls. To minimize interstudy methodologic differences, we used a published real-time polymerase chain reaction (PCR)-based assay. The proportion of patients with increased neutrophil PRV-1 expression was 83% in PV, 21% in ET, 42% in MMM, 18% in SP, and 0% in controls. All 5 MMM patients with PRV-1 up-regulation had an antecedent history of PV. We conclude that neutrophil PRV-1 up-regulation is a characteristic feature of PV that may not be affected by fibrotic transformation. However, quantifying neutrophil PRV-1 mRNA, while complementary to other tests, is not in itself sufficient for the diagnosis of PV. (Blood. 2004;103:3547-3548)<\/jats:p>","DOI":"10.1182\/blood-2003-10-3505","type":"journal-article","created":{"date-parts":[[2004,1,5]],"date-time":"2004-01-05T20:12:45Z","timestamp":1073333565000},"page":"3547-3548","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia"],"prefix":"10.1182","volume":"103","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Wolanskyj","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223023861000_REF1","doi-asserted-by":"crossref","unstructured":"Wasserman LR. The management of polycythaemia vera. Br J Haematol.1971;21: 371-376.","DOI":"10.1111\/j.1365-2141.1971.tb02698.x"},{"key":"2020021223023861000_REF2","doi-asserted-by":"crossref","unstructured":"Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc.2003;78: 174-194.","DOI":"10.4065\/78.2.174"},{"key":"2020021223023861000_REF3","doi-asserted-by":"crossref","unstructured":"Dobo I, Mossuz P, Campos L, et al. Comparison of four serum-free, cytokine-free media for analysis of endogenous erythroid colony growth in polycythemia vera and essential thrombocythemia. Hematol J.2001;2: 396-403.","DOI":"10.1038\/sj.thj.6200123"},{"key":"2020021223023861000_REF4","doi-asserted-by":"crossref","unstructured":"Moliterno AR, Spivak JL. Posttranslational processing of the thrombopoietin receptor is impaired in polycythemia vera. Blood.1999;94: 2555-2561.","DOI":"10.1182\/blood.V94.8.2555.420k14_2555_2561"},{"key":"2020021223023861000_REF5","doi-asserted-by":"crossref","unstructured":"Tefferi A, Yoon SY, Li CY. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis. Blood.2000;96: 771-772.","DOI":"10.1182\/blood.V96.2.771"},{"key":"2020021223023861000_REF6","doi-asserted-by":"crossref","unstructured":"Temerinac S, Klippel S, Strunck E, et al. Cloning of PRV-1, a novel member of the uPAR receptor superfamily, which is overexpressed in polycythemia rubra vera. Blood.2000;95: 2569-2576.","DOI":"10.1182\/blood.V95.8.2569"},{"key":"2020021223023861000_REF7","doi-asserted-by":"crossref","unstructured":"Klippel S, Strunck E, Temerinac S, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood.2003;102: 3569-3574.","DOI":"10.1182\/blood-2003-03-0919"},{"key":"2020021223023861000_REF8","doi-asserted-by":"crossref","unstructured":"Liu E, Jelinek J, Pastore YD, Guan Y, Prchal JF, Prchal JT. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and BFU-E response to erythropoietin. Blood.2003;101: 3294-3301.","DOI":"10.1182\/blood-2002-07-2287"},{"key":"2020021223023861000_REF9","doi-asserted-by":"crossref","unstructured":"Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood.2003;102: 1869-1871.","DOI":"10.1182\/blood-2003-03-0744"},{"key":"2020021223023861000_REF10","doi-asserted-by":"crossref","unstructured":"Pearson TC. Evaluation of diagnostic criteria in polycythemia vera. Semin Hematol.2001;38: 21-24.","DOI":"10.1016\/S0037-1963(01)90136-2"},{"key":"2020021223023861000_REF11","unstructured":"Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol.1999;36: 9-13."},{"key":"2020021223023861000_REF12","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. WHO Classification of Tumors: Tumors of the Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"2020021223023861000_REF13","doi-asserted-by":"crossref","unstructured":"Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol.2003;82: 148-152.","DOI":"10.1007\/s00277-002-0604-y"},{"key":"2020021223023861000_REF14","doi-asserted-by":"crossref","unstructured":"Teofili L, Martini M, Luongo M, et al. Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia. J Clin Oncol.2002;20: 4249-4254.","DOI":"10.1200\/JCO.2002.11.507"},{"key":"2020021223023861000_REF15","unstructured":"Fruehauf S, Topaly J, Villalobos M, Veldwijk MR, Laufs S, Ho AD. Quantitative real-time polymerase chain reaction shows that treatment with interferon reduces the initially upregulated PRV-1 expression in polycythemia vera patients. Haematologica.2003;88: 349-351."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/9\/3547\/1699032\/zh800904003547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/9\/3547\/1699032\/zh800904003547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T23:02:50Z","timestamp":1581548570000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/9\/3547\/18551\/Neutrophil-PRV1-expression-across-the-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,1]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,5,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-10-3505","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,1]]}}}